MRSA Nasal Screening for Pneumonia

In adults with community-acquired pneumonia (CAP), obtain MRSA nasal PCR when empiric MRSA coverage is contemplated because of a validated risk factor, particularly prior respiratory isolation of MRSA. Obtain respiratory cultures concurrently when feasible; nasal PCR is used to support continuation or withdrawal of the added MRSA agent rather than to replace pathogen-directed cultures. BMJBMJCommunity-acquired pneumonia in adults - BMJ Best Practice

For CAP with recent hospitalization and receipt of parenteral antibiotics during the preceding 90 days, apply this as a trigger for cultures and MRSA nasal PCR only if the association with MRSA has been locally validated. If PCR and cultures are negative, withhold added MRSA coverage; if either is positive, begin additional coverage while interpreting the result against the respiratory syndrome and available microbiology. BMJBMJCommunity-acquired pneumonia in adults - BMJ Best Practice

In suspected ventilator-associated pneumonia (VAP), MRSA nasal swab testing should be incorporated into the initial microbiologic strategy when empiric anti-MRSA therapy is under consideration. The empiric regimen must also account for prior patient culture data, recent antibiotic exposure, local susceptibility patterns, and when the infection developed during hospitalization. BMJBMJFever and infections in surgical intensive care: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document | Trauma Surgery & Acute Care Open

A negative MRSA nasal swab or PCR makes MRSA an unlikely cause of pneumonia and can support stopping or avoiding empiric anti-MRSA treatment when the patient has no compelling microbiologic or clinical evidence of MRSA lower-respiratory infection. This negative-result strategy is specifically endorsed in CAP pathways that use PCR or culture findings to withhold added coverage and in VAP guidance that uses a negative swab to obviate MRSA coverage. BMJ+2BMJCommunity-acquired pneumonia in adults - BMJ Best PracticeBMJFever and infections in surgical intensive care: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document | Trauma Surgery & Acute Care OpenacpjournalsHow Would You Treat This Patient Hospitalized With Community ...

A positive MRSA nasal screen should not be equated with MRSA pneumonia. Treat it as evidence that prevents rule-out rather than as proof of the etiologic pathogen, and obtain or review respiratory cultures before committing to prolonged targeted therapy. In CAP with a positive PCR or culture under a locally validated MRSA-risk pathway, additional MRSA coverage should be started; the respiratory culture and clinical trajectory then determine whether it remains necessary. BMJ+1BMJCommunity-acquired pneumonia in adults - BMJ Best PracticeacpjournalsHow Would You Treat This Patient Hospitalized With Community ...

Do not delay appropriate empiric therapy in a patient with strong suspicion for VAP while awaiting screening or culture results. Initial ineffective therapy is associated with higher mortality in VAP, whereas no single empiric regimen is generally superior across settings; select coverage from the local antibiogram and patient-specific resistance history, then narrow when results return. BMJBMJFever and infections in surgical intensive care: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document | Trauma Surgery & Acute Care Open

For hospitalized CAP with prior respiratory MRSA isolation, obtain cultures and initiate empiric MRSA-active therapy in addition to standard CAP treatment. Reassess at 48 hours: if cultures do not identify a drug-resistant pathogen and the patient is clinically improving, de-escalation to standard CAP therapy should be considered. BMJBMJCommunity-acquired pneumonia in adults - BMJ Best Practice

For the narrower group with recent hospitalization and parenteral antibiotics within 90 days, do not automatically add MRSA therapy unless the risk factor has been locally validated. Obtain cultures and nasal PCR first; negative results support withholding the additional agent, whereas positive results prompt initiation of additional coverage. BMJBMJCommunity-acquired pneumonia in adults - BMJ Best Practice

The screening test should not substitute for severity assessment or disposition decisions. CAP care still requires severity-based selection of outpatient versus inpatient treatment, with PSI or CURB-65 used for risk stratification in guideline-based practice. ScienceDirectScienceDirectPneumonia Severity Index - an overview | ScienceDirect Topics

When suspicion for VAP is strong, begin empiric therapy directed at Staphylococcus aureus, Pseudomonas, and other gram-negative bacilli after obtaining appropriate cultures. Common regimens include vancomycin plus cefepime or piperacillin-tazobactam; for severe penicillin allergy, aztreonam is an alternative partner. No specific empiric regimen is generally superior, so regimen selection should be individualized to the local antibiogram and patient resistance history. BMJBMJFever and infections in surgical intensive care: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document | Trauma Surgery & Acute Care Open

Use MRSA nasal swab testing to decide whether empiric MRSA coverage remains necessary. A negative test can obviate MRSA coverage; when cultures become available, de-escalate to the narrowest active regimen. Routine empiric anaerobic coverage is not recommended for VAP. BMJBMJFever and infections in surgical intensive care: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document | Trauma Surgery & Acute Care Open

For most VAP episodes, seven days of antimicrobial treatment is sufficient. Extend or alter treatment only when microbiology, complications, or failure of clinical improvement provides a specific reason to do so rather than because the nasal screen is positive. BMJBMJFever and infections in surgical intensive care: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document | Trauma Surgery & Acute Care Open

The common failure is ordering a nasal test without linking it to an actionable stop rule. For pneumonia, document at the time of prescribing whether the anti-MRSA agent will be stopped for a negative nasal result, negative cultures, or both; in CAP, reassess the expanded regimen by 48 hours if the patient is improving and cultures do not identify a resistant pathogen. BMJBMJCommunity-acquired pneumonia in adults - BMJ Best Practice

Do not broaden treatment from a positive screening test alone. A positive result has a different clinical meaning from a prior respiratory MRSA isolate or a current respiratory culture because nasal carriage does not establish lower-respiratory infection. BMJ+1BMJCommunity-acquired pneumonia in adults - BMJ Best PracticeacpjournalsHow Would You Treat This Patient Hospitalized With Community ...

Do not use the nasal result to bypass culture acquisition in severe pneumonia. Cultures are needed to identify alternative resistant pathogens, validate continuation of expanded therapy, and direct de-escalation. In VAP, treatment selection additionally depends on local epidemiology and prior patient microbiology. BMJ+1BMJCommunity-acquired pneumonia in adults - BMJ Best PracticeBMJFever and infections in surgical intensive care: an American Association for the Surgery of Trauma Critical Care Committee clinical consensus document | Trauma Surgery & Acute Care Open